Torres-Soriano Mitzy E, García-Aguirre Gerardo, Kon-Jara Verónica, Ustariz-Gonzáles Orlando, Abraham-Marín Maura, Ober Michael D, Quiroz-Mercado Hugo
Retina Service, Asociacion Para Evitar la Ceguera, Hospital Dr. Luis Sánchez Bulnes, Vicente García Torres 46, San Lucas Coyoacan, 04030 Coyoacan, México City, México.
Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1235-9. doi: 10.1007/s00417-008-0856-x. Epub 2008 Jun 4.
We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC).
Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual acuity, fluorescein angiography and optical coherent tomography before, 1, 3 and 6 months after treatment.
All patients showed improvement in visual acuity, fluorescein angiographic leakage, and reduced or resolved neurosensory detachment following treatment.
Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.
我们报告玻璃体内注射贝伐单抗作为治疗中心性浆液性脉络膜视网膜病变（CSC）的一种新选择。
5例继发于CSC的视网膜色素上皮（RPE）渗漏患者接受了玻璃体内注射贝伐单抗（2.5 mg/0.1 cc），并在治疗前、治疗后1个月、3个月和6个月进行了最佳矫正视力、荧光素血管造影和光学相干断层扫描检查。
所有患者治疗后视力均有改善，荧光素血管造影显示渗漏减轻，神经感觉层脱离减轻或消失。
玻璃体内注射贝伐单抗可改善CSC患者的视力，减轻神经感觉层脱离，且无不良事件发生。尽管这些结果很有前景，但进一步的研究将有助于了解这种针对CSC患者的治疗方法。
